ESTIMATION OF LONG‐TERM SURVIVAL WITH TAFASITAMAB + LENALIDOMIDE (LEN) IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). (17th June 2021) - Salles, G; Goswami, B; Bagnardi, V; Dey, D; Winderlich, M; Ambarkhane, S; Huang, D; Nowakowski, G. S